Issue 4/2016
Content (15 Articles)
The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells
Francesca De Iuliis, Ludovica Taglieri, Gerardo Salerno, Anna Giuffrida, Bernardina Milana, Sabrina Giantulli, Simone Carradori, Ida Silvestri, Susanna Scarpa
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells
Bo Mi Ku, Yeon-Hee Bae, Jiae Koh, Jong-Mu Sun, Se-hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice
Bence Kapuvári, Rózsa Hegedüs, Ákos Schulcz, Marilena Manea, József Tóvári, Alexandra Gacs, Borbála Vincze, Gábor Mező
Peloruside A, a microtubule-stabilizing agent, induces aneuploidy in ovarian cancer cells
Ariane Chan, A. Jonathan Singh, Peter T. Northcote, John H. Miller
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
Shailender Bhatia, Anna C. Pavlick, Peter Boasberg, John A. Thompson, George Mulligan, Michael D. Pickard, Hélène Faessel, Bruce J. Dezube, Omid Hamid
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
Eric X. Chen, Derek J. Jonker, Lillian L. Siu, Karyn McKeever, Deborah Keller, Julie Wells, Linda Hagerman, Lesley Seymour
Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin
Christopher C. Coss, Amanda Jones, James T. Dalton
Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases
Michiro Takahashi, Kiyoshi Hasegawa, Masaru Oba, Akio Saiura, Junichi Arita, Yoshihiro Sakamoto, Eiji Shinozaki, Nobuyuki Mizunuma, Yutaka Matsuyama, Norihiro Kokudo
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer
Joseph Kattan, Marwan Bachour, Fadi Farhat, Elie El Rassy, Tarek Assi, Marwan Ghosn
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer
Paul L. Swiecicki, Emily Bellile, Assuntina G. Sacco, Alexander T. Pearson, Jeremy M. G. Taylor, Trachette L. Jackson, Douglas B. Chepeha, Matthew E. Spector, Andrew Shuman, Kelly Malloy, Jeffrey Moyer, Erin McKean, Scott McLean, Ammar Sukari, Gregory T. Wolf, Avraham Eisbruch, Mark Prince, Carol Bradford, Thomas E. Carey, Shaomeng Wang, Jacques E. Nör, Francis P. Worden
Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer
Seiichiro Suzuki, Masato Karayama, Naoki Inui, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Shigeki Kuroishi, Hiroyuki Matsuda, Koshi Yokomura, Naoki Koshimizu, Mikio Toyoshima, Shiro Imokawa, Kazuhiro Asada, Masafumi Masuda, Takashi Yamada, Hiroshi Watanabe, Takafumi Suda
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies
Yaghoub Safdari, Vahideh Ahmadzadeh, Safar Farajnia
Why balls are not put inside the basket? A reflection on testicular cancer clinical trial design
Hampig Raphael Kourie, Fouad Aoun
Peptide aptamer identified by molecular docking targeting translationally controlled tumor protein in leukemia cells
Onat Kadioglu, Thomas Efferth
The imidazoline compound RX871024 promotes insulinoma cell death independent of AMP-activated protein kinase inhibition
Irina I. Zaitseva, Sergei V. Zaitsev, Per-Olof Berggren